Krishnan Nandabalan

Krishnan Nandabalan is a declared insider of BioXcel Therapeutics, Inc. (board member), with filings sourced from SEC (Form 4). The record holds 19 filings, for trades running from 29 November 2018 to 6 April 2023.

In open-market terms, that means 1 purchase worth €4,328 on one side and 8 sales worth €15.3M on the other. The net balance comes to €15.3M on the selling side. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Other entries cover 5 option exercises. So far in 2023, the count stands at no purchases and 5 sales.

The latest filing, published on 10 April 2023, reports an open-market sale of €952k in BioXcel Therapeutics, Inc. The most recent open-market purchase was published on 30 November 2018, 2,901 days ago. Typically, a trade is published a median of 4 days after it takes place. Section 16 rules allow two business days to file each Form 4. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.